CJC NO DAC + IPA
Testing pending — unavailable for purchase until documentation is received, reviewed, and matched
Choose labeled amount
Current list price
$58.00
5 mg + 5 mg (10 mg total) · single vial
Use restrictions
Poise materials are supplied solely for nonclinical laboratory work. Do not administer them to people or animals or use them for self-experimentation, clinical investigation or diagnosis. Food, cosmetic, household and treatment applications are excluded.
Testing Report (COA)
No reports are currently published on this website for this item.
Compound Information
- Identity
- Two-component peptide blend of modified GRF(1-29)/CJC-1295 without DAC and ipamorelin.
- Physical form
- Supplied as a solid in a vial. Consult the applicable lot record for appearance details.
- Selected composition
- Modified GRF(1–29) / CJC-1295 without DAC: 5 mg · Ipamorelin: 5 mg
- Lot boundary
- Reference chemistry and sequences do not prove a supplied lot’s identity or composition. The label and lot record define the supported composition details. Excipients, counter-ions and hydration are unspecified unless those records identify them.
- Mixture chemistry
- Multiple distinct components; no single molecular formula, molecular weight or mixture CAS identifier is asserted.
- Storage boundary
- Use the conditions specified for the exact lot, including any temperature limits. Protect the closed container from moisture and light, document excursions, and do not assume a shelf life that the supporting record does not establish.
- Handling boundary
- Handling is restricted to personnel trained for laboratory work. Choose protective equipment and containment under your institution's procedures, prevent material from contacting skin or eyes, and avoid creating airborne particles.
Reference depiction
Molecular structure
Defined multi-component blend — no single molecular structure. Labeled components are depicted individually.
CJC-1295 no DAC · 5 mg
RDKit sequence-derived 2D depiction · Reference CID 91976842 · 2026-10-13Drawn from Table 1 including D-Ala at residue 2 and C-terminal amidation; CID 91976842 leaves peptide stereocenters unspecified.
Ipamorelin · 5 mg
RDKit 2D depiction of PubChem SDF · Reference CID 9831659 · 2026-10-13
Modified GRF(1–29) / CJC-1295 without DAC
- Reference identity
- Modified GRF(1–29) / CJC-1295 without DAC
- Residue count
- 29 residues
- Reference formula
- C152H252N44O42
- Molecular weight
- 3367.9 g/mol (reference representation)
- Reference CAS
- No form-specific CAS identifier is asserted for this reference representation.
- Reference sequence
- H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2Sequence source
- Reference notes
- D-Ala at residue 2 and a C-terminal amide; no drug-affinity complex (DAC).
- Chemical source
- PubChem CID 91976842
Ipamorelin
- Reference identity
- Ipamorelin
- Residue count
- 5 residues
- Reference formula
- C38H49N9O5
- Molecular weight
- 711.9 g/mol (reference representation)
- Reference CAS
- 170851-70-4
- Reference sequence
- H-Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Reference notes
- Aib is alpha-aminoisobutyric acid; 2-Nal is 2-naphthylalanine. D-2-Nal and D-Phe stereochemistry and the C-terminal amide are part of this reference identity.
- Chemical source
- PubChem CID 9831659
Research literature
Published research is separate from the evidence for a supplied vial. These links identify literature about the material, not findings for your selected amount or instructions for use.
These studies examine individual components. No study of this exact blend and ratio has been verified.
Component: CJC-1295 without DAC
Detection of GHRH synthetic analogsMemdouh S et al. · Drug Testing and Analysis · 2021
Analytical method study · In vitro metabolism systems and fortified urine samples
Findings: Researchers characterized metabolites of GHRH analogs, including CJC-1295 without DAC, and developed a sensitive LC-MS/MS detection method.
Limitations: This study concerns chemical identification and metabolism, not clinical efficacy; findings about CJC-1295 with DAC cannot be transferred to the no-DAC form.
DOI: 10.1002/dta.3183